TARGETS MIGRAINE PAIN FAST1


• Effective migraine relief in 30 minutes1


• Relieves migraine headache attacks with or without aura1


• Effective in treating menstrual migraine1


Order now: Pack Size


RRP* (£) Migraitan 2s £8.00


Listed Trade


Price (£) £4.24


PIP Code 388-4616


EAN Code 5060013943003 www.bristol-labsconsumercare.co.uk


PRESCRIBING INFORMATION Product Name: Migraitan 50mg Film–coated tablets. Composition: Sumatriptan succinate 50mg. See SmPC for full list of excipients. Indication: Acute relief of migraine attacks, with or without aura. Posology and method of administration: Not to be taken prophylactically. Recommended as a monotherapy, not to be given with ergotamine or ergotamine derivatives. Adults (18 to 65 years): Single 50mg tablet swallowed with water. Some patients may require 100mg. If no response to first tablet, no further tablet to be taken. If response, and symptoms recur, a second tablet may be taken in next 24 hours but at least 2 hours after first tablet. No more than 300mg to be taken in each 24 hour period. Elderly (over 65 years): Not recommended. Children: (less than 10 years): No clinical data, (10-17 years): Not recommended Mild to moderate Hepatic impairment: 25-50mg; Renal impairment: Use with caution. Contraindications: Those with:- previous myocardial infarction, ischaemic heart disease, coronary vasospasm, vascular disease,signs consistent with ischaemic heart disease, moderate and severe hypertension, mild uncontrolled hypertension, history of stroke, transient ischaemic attack, severe hepatic impairment, concomitant use with:- ergotamine, ergotamine derivatives, 5HT-1 receptor agonists, reversible or irreversible MAOIs. Patients with a known hypersensitivity to sulphonamides. Those with a known hypersensitivity to sumatriptan or any of the tablet ingredients. Special warnings and precautions for use: Only to be used with a clear diagnosis of migraine. Not for use with hemiplegic, basilar or ophthalmologic migraine. Before treating headaches, care should be taken to exclude other potentially serious neurological conditions. Sumatriptan can be associated with transient symptoms of chest pain and tightness involving the throat. Not to be used in patients in whom unrecognized cardiac disease is likely without prior medical assessment. Special consideration should be given to post-menopausal women and males aged over 40 years. Rare reports reported of serotonin syndrome, asthenia, hyper-reflexia and incoordination following concomitant use of SSRIs and sumatriptan. Treat with caution in patients with hepatic and renal impairment, history of seizures, controlled hypertension. Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, should not take this medicine. The recommended dose should not be exceeded. Interactions with other medicinal products: Potential interaction with MAOIs, ergotamine or ergotamine derivatives, other triptan/5HT-1 receptor agonists. Contraindicated for concomitant administration with MAOIs and ergotamine. Advised to wait for at least 24 hours following use of ergotamine containing preparations or other triptan / 5HT1 receptor agonists before sumatriptan use. Advised to wait 6 hours post sumatriptan use before use of ergotamine containing products and 24 hours before triptan / 5HT1 receptor agonists. Serotonin syndrome reported in patients following co-administration with SSRIs, SNRIs and triptans. Risk of serotonin syndrome when co-administered with lithium. Pregnancy and lactation: Should only be considered if the expected benefits to the mother are greater than the possible risk to the foetus. Sumatriptan is excreted in breast milk. Minimise infant exposure by avoiding breast feeding for 12 hours after treatment. During these 12 hours, expressed milk should be discarded. Driving ability/use of machines: Drowsiness may occur as a result of migraine or its treatment with sumatriptan. Undesirable effects: Some symptoms may be associated with migraine. Common effects; Dizziness, drowsiness, sensory disturbance, transient blood pressure increases, dyspnea, nausea, vomiting, sensation of heaviness, myalgia, pain, sensations of heat, cold, pressure, tightness, weakness or fatigue; see SmPC for full list of side-effects. Overdose: Seek medical advice. Product Licence Holder: Bristol Laboratories Limited, Unit 3, Canalside Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG (PL 17907/0240). Date of Authorisation: 08/05/09. Recommended Price: £ 8.00, 2 Tablet Packs. Date of Prescribing Information: 02.03.2015 P


Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard


Adverse events should also be reported to Bristol Laboratories Medical Information Department on Telephone: 0044 (0)1442 200922


References: 1. Migraitan®


SPC February 2015


* Recommended Retail Price Date of preparation: June 2016 Code: UK/MIG/ADV17faa/06/2016


Quality • Consistency • Excellence www.bristol-labs.co.uk


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64